Arne Kristian Skulberg
- Senior Physician, Researcher; MD, PhD
- arnsku@ous-hf.no
I have been working on opioid overdoses, and the development of a naloxone nasal spray together with Prof. Ola Dale and NTNU for the last decade. This has involved pharmacokinetic studies in heathy volunteers and a larger randomized trial comparing intranasal and intramuscular naloxone administered by Ambulance works in Oslo and Trondheim.
I work as a consultant anesthetist at Legebilen 119, a physician manned ambulance in the Oslo Metropolitan area.
Publications 2024
Heightened mortality risk after a non-fatal opioid overdose: Risk factors for mortality in the week following emergency treatment
Addiction, 119 (12), 2131-2138
DOI 10.1111/add.16632, PubMed 39183709
[Not Available]
Tidsskr Nor Laegeforen, 144 (8)
DOI 10.4045/tidsskr.24.0202, PubMed 38934313
Publications 2022
Inhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trial
PLoS One, 17 (5), e0268822
DOI 10.1371/journal.pone.0268822, PubMed 35622848
Naloxone administration-no balance without titration
Addiction, 117 (10), 2750-2751
DOI 10.1111/add.15947, PubMed 35589622
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial
Addiction, 117 (6), 1658-1667
DOI 10.1111/add.15806, PubMed 35137493
Publications 2021
REBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trial
Trials, 22 (1), 511
DOI 10.1186/s13063-021-05477-1, PubMed 34332617
Intranasal Naloxone Administration
N Engl J Med, 384 (24), e96
DOI 10.1056/NEJMc2106983, PubMed 34133872
Intranasal Naloxone Administration REPLY
N. Engl. J. Med., 384 (24)
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
Eur J Clin Pharmacol, 77 (12), 1901-1908
DOI 10.1007/s00228-021-03190-1, PubMed 34327552
Publications 2020
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use
BMJ Open, 10 (11), e041556
DOI 10.1136/bmjopen-2020-041556, PubMed 33184084
Prehospital naloxone administration - what influences choice of dose and route of administration?
BMC Emerg Med, 20 (1), 71
DOI 10.1186/s12873-020-00366-3, PubMed 32891142
Publications 2019
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial
Addiction, 114 (5), 859-867
DOI 10.1111/add.14552, PubMed 30644628
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
Tidsskr Nor Laegeforen, 139 (13)
DOI 10.4045/tidsskr.19.0162, PubMed 31556537
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
Tidsskr. Nor. Laegeforen., 139 (13), 1260-1264
Publications 2018
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
Subst Abus, 40 (3), 383-388
DOI 10.1080/08897077.2018.1485130, PubMed 29949448
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers
Eur J Clin Pharmacol, 74 (7), 873-883
DOI 10.1007/s00228-018-2443-3, PubMed 29568976
Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil
Eur J Clin Pharmacol, 74 (12), 1547-1553
DOI 10.1007/s00228-018-2545-y, PubMed 30143830
Publications 2017
Pharmacokinetics of a new, nasal formulation of naloxone
Eur J Clin Pharmacol, 73 (5), 555-562
DOI 10.1007/s00228-016-2191-1, PubMed 28144724
Publications 2016
[Treatment of air embolisms]
Tidsskr Nor Laegeforen, 136 (12-13), 1070
DOI 10.4045/tidsskr.16.0455, PubMed 27381784